Guidance: Assessing Adhesion with Transdermal and Topical Delivery Systems for Abbreviated New Drug Applications
FDA issued guidance on assessing adhesion for transdermal and topical delivery systems in ANDAs, providing recommendations for demonstrating product quality and performance.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 31, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Generic drug manufacturers developing transdermal and topical delivery systems, including ANDA applicants and contract manufacturers. should confirm how it applies to their specific situation before acting. There is a time constraint attached: No specific deadline provided; guidance is effective immediately but does not impose a compliance date.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
New FDA guidance outlines recommended approaches for evaluating adhesion properties of transdermal and topical products in abbreviated new drug applications.
Who it affects
Generic drug manufacturers developing transdermal and topical delivery systems, including ANDA applicants and contract manufacturers.
What you must do
Review the guidance and assess whether current adhesion testing methods align with FDA recommendations for upcoming or ongoing ANDA submissions.
Deadline
No specific deadline provided; guidance is effective immediately but does not impose a compliance date.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Novo Nordisk’s Bloomington Plant Receives FDA OAI Designation Following Contamination and Compliance Issues - pharmaceuticalcommerce.com
- Uyghur Forced Labor Prevention Act Entity List
- Final Debarment Order: Ricardo Andres Acuna
- Final Debarment Order: Angela Anatilde Baquero
- Guidance: Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts